Deutsche Bank Ag\ Design Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 28,094 shares of DSGN stock, worth $157,888. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,094

Previous 28,094 -0.0%

Holding current value

$157,888

Previous $94,000 60.64%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.99 - $2.76 $54,894 - $76,134	27,585 Added 5419.45%	28,094 $74,000
Q3 2023 Nov 09, 2023	SELL	$2.05 - $8.14 $31,553 - $125,290	-15,392 Reduced 96.8%	509 $1,000
Q2 2023 Aug 14, 2023	SELL	$4.99 - $7.64 $44,685 - $68,416	-8,955 Reduced 36.03%	15,901 $100,000
Q1 2023 May 15, 2023	BUY	$5.5 - $9.77 $38,582 - $68,536	7,015 Added 39.32%	24,856 $143,000
Q4 2022 Feb 13, 2023	BUY	$7.86 - $17.2 $32,084 - $70,210	4,082 Added 29.67%	17,841 $183,000
Q3 2022 Nov 14, 2022	SELL	$14.09 - $25.57 $31,857 - $57,813	-2,261 Reduced 14.11%	13,759 $230,000
Q2 2022 Aug 11, 2022	BUY	$9.91 - $17.33 $12,189 - $21,315	1,230 Added 8.32%	16,020 $224,000
Q1 2022 May 13, 2022	SELL	$11.17 - $20.89 $24,886 - $46,542	-2,228 Reduced 13.09%	14,790 $239,000
Q4 2021 Feb 11, 2022	BUY	$13.64 - $21.41 $122,800 - $192,754	9,003 Added 112.33%	17,018 $364,000
Q3 2021 Nov 04, 2021	BUY	$13.99 - $20.03 $209 - $300	15 Added 0.19%	8,015 $118,000
Q2 2021 Aug 11, 2021	BUY	$19.02 - $29.78 $152,160 - $238,240	8,000 New	8,000 $159,000

Others Institutions Holding DSGN

# of Institutions

102

Shares Held

31M

Call Options Held

2.3K

Put Options Held

16.5K

View Full List

About Design Therapeutics, Inc.

Ticker DSGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,807,900
Market Cap $314M
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...

More about DSGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account